Abstract Treatment of Chronic Myeloid Leukaemia (CML) has evolved rapidly in the last 10
years. The objectives of this national consensus meeting were to describe the optimal …

Introduction The treatment of chronic myeloid leukemia (CML) has been drastically changed
by the approval of tyrosine kinase inhibitors (TKIs). CML is now managed as a chronic …

The advent of tyrosine kinase inhibitors (TKI) into the management of patients with chronic
myeloid leukemia (CML) has profoundly improved prognosis. Survival of responders is …

Chronic myeloid leukemia (CML) is the best example of successful targeted therapy. Today,
the overall survival of patients with CML treated by using tyrosine kinase inhibitors (TKIs) is …

Tyrosine kinase inhibitors (TKIs) represent a major breakthrough in the treatment of chronic
myeloid leukemia (CML). Thanks to these agents, CML has been transformed from a …

Excellent therapeutic options exist for the treatment of chronic-phase chronic myeloid
leukemia (CML) patients. Therefore, managing CML patients has become a more common …

Chronic myeloid leukemia (CML) is a stem cell disease characterized by the BCR/ABL
oncoprotein. The ABL kinase inhibitor imatinib is effective in most patients and considered …

Introduction: Several recent studies have shown the speed and depth of response to
tyrosine kinase inhibitor (TKI) treatment to be an important indicator of patient outcomes in …

The introduction of tyrosine kinase inhibitors (TKI) has dramatically changed the outcome of
chronic myeloid leukemia (CML). Over the last decade, imatinib positioned itself as the gold …

Background: With the dramatic success of tyrosine kinase inhibitors (TKI) to treat Chronic
myeloid leukemia (CML), the life expectancy of CML patients is now close to that of the …